Citation

Shah SK, He S, Guo L, Truong Q, Qi H, Du W, Lai Z, Liu J, Jian T, Hong Q, Dobbelaar P, Ye Z, Sherer E, Feng Z, Yu Y, Wong F, Samuel K, Madiera M, Karanam BV, Reddy VB, Mitelman S, Tong SX, Chicchi GG, Tsao KL, Trusca D, Feng Y, Wu M, Shao Q, Trujillo ME, Eiermann GJ, Li C, Pachanski M, Fernandez G, Nelson D, Bunting P, Morissette P, Volksdorf S, Kerr J, Zhang BB, Howard AD, Zhou YP, Pasternak A, Nargund RP, Hagmann WK.: Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes. ACS Med Chem Lett, Volume 6 (5), 2015

Authors

Bunting P, Chicchi GG, Dobbelaar P, Du W, Eiermann GJ, Feng Y, Feng Z, Fernandez G, Guo L, Hagmann WK., He S, Hong Q, Howard AD, Jian T, Karanam BV, Kerr J, Lai Z, Li C, Liu J, Madiera M, Mitelman S, Morissette P, Nargund RP, Nelson D, Pachanski M, Pasternak A, Qi H, Reddy VB, Samuel K, Shah SK, Shao Q, Sherer E, Tong SX, Trujillo ME, Truong Q, Trusca D, Tsao KL, Volksdorf S, Wong F, Wu M, Ye Z, Yu Y, Zhang BB, Zhou YP

Journal

ACS Med Chem Lett

Year

2015

DOI

10.1021/ml500514w

PubMed

26005524

Machine-readable

REST APIRDF